Merrimack Pharmaceuticals (MACK)
(Delayed Data from NSDQ)
$15.00 USD
-0.03 (-0.20%)
Updated May 3, 2024 04:00 PM ET
After-Market: $15.00 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MACK 15.00 -0.03(-0.20%)
Will MACK be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for MACK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MACK
The Zacks Analyst Blog Highlights Merrimack Pharmaceuticals, Moderna and Seagen
Biotech Stock Roundup: MACK Up on Study Data, MRNA Offers Vaccine Update & More
MACK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for MACK
Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution
Merrimack Pharmaceuticals announces notification of plan to delist common stock on Nasdaq
Merrimack Pharmaceuticals Announces Nasdaq Delisting and Liquidation Plan
Merrimack to voluntary delist common stock on Nasdaq
Merrimack Receives $225 Million Milestone Payment from Ipsen